What's new from the EAU?

With the 39th Annual EAU Congress (EAU24)?just around the corner, excitement is building within our urology community, and we look forward to seeing many of you in Paris next month! In the meantime, here is your monthly dose of engaging urology news.

Survey results on surgical training in Europe

Results from the recent ESRU, YAU, ESU, and EAU survey on surgical training in Europe concluded that the current distribution of surgical training centres falls short in ensuring widespread access to standardised training programmes. While dry lab facilities are relatively widespread, the availability of wet lab resources remains restricted. There is an urgent need for continued efforts to establish uniform training routes and assessment techniques across various surgical methodologies. Learn more.

The multicentre SAFER study

Artificial urinary sphincter (AUS) erosion is a significant complication in the management of male stress urinary incontinence, but there is a lack of standardisation in its treatment. The multicentre SAFER study (Systematic Assessment of Artificial Urinary Sphincter Failure and Erosion Recovery) is a retrospective cohort investigation, designed to elucidate the most effective treatment modalities for the erosion of AUS. Interested researchers and institutions are encouraged to participate. Read more .

New EAU Book: Interview with Prof. Schultheiss

For 2024, the EAU History Office has a new Congress Gift lined up for EAU members in Paris. Representing the culmination of several years’ work, Urology in Art is a collaboration between five History Office members, each contributing from his own area of interest. Together, the book examines cultural representations and paints a picture (!) of urology and the urologist throughout the ages. Read the interview with Prof. Dirk Schultheiss (DE), former chairman of the EAU History Office and “initiating author” of this research project.

An objective evaluation of focal therapy

JUPITER is the prospective multicentre European registry for patients undergoing focal therapy for localised PCa, and it is nearly ready to launch. The aim is to recruit at least 1,000 patients from an unlimited number of European centres over the next 2 years. Eligible patients must have a life expectancy of over 10 years, be diagnosed with intermediate-risk PCa, feature a lesion detected on a multiparametric MRI, and have undergone both targeted and systematic biopsies using a US-MRI fusion technique, resulting in the discovery of PCa with an ISUP grade of ≤3 within the target area. Contact [email protected] to join the community of doctors involved.

Join us in Budapest for critical updates in PCa, BCa and RCC

The UROonco24 early fee discount ends today (21 March, 23:59 CET). This European onco-urology meeting represents a dynamic learning platform where experts and delegates can share knowledge, deliberate on the latest research, and pave the way together to improve patient outcomes. Register here to join the experts in Budapest from 20 - 22 June and get all your updates in prostate cancer, bladder cancer, kidney cancer and rare tumours!